Long-term antibody persistence study (3 years after last dose) of the 7-valent pneumococcal conjugate vaccine in young children in China  by Li, Rongcheng et al.
Vaccine 34 (2016) 5359–5365Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vacc ineLong-term antibody persistence study (3 years after last dose)
of the 7-valent pneumococcal conjugate vaccine in young
children in Chinahttp://dx.doi.org/10.1016/j.vaccine.2016.08.070
0264-410X/ 2016 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations: DTaP, routine diphtheria, tetanus, and acellular pertussis; GMC,
geometric mean concentration; GMFC, geometric mean fold change; IgG,
immunoglobulin G; PCV7, 7-valent pneumococcal conjugate vaccine.
⇑ Corresponding author at: Vaccine Clinical Research, Pfizer Inc, 500 Arcola Road,
Collegeville, PA 19426, USA.
E-mail addresses: lrch2001@163.com (R. Li), fkx.08@163.com (K.-X. Fang),
mariano.young-jr@pfizer.com (M. Young Jr.), zhoujdr@163.com (X. Zhou),
zhangjing.chen@astrazeneca.com (Z. Chen), john.liang@pfizer.com (J.Z. Liang),
peter.giardina@pfizer.com (P.C. Giardina), dan.scott@pfizer.com (D.A. Scott).
1 Former employee of Pfizer Inc, Shanghai, China.Rongcheng Li a, Kong-Xiong Fang b, Mariano Young Jr. c,⇑, Xin Zhou d,1, Zhangjing Chen d,1,
John Z. Liang c, Peter C. Giardina e, Daniel A. Scott e
aGuangxi Center for Disease Control and Prevention, Center for Vaccine Clinical Research, Guangxi, China
b Longgang County CDC, Guangxi, China
cPfizer Inc, Collegeville, PA, USA
d Pfizer Inc, Shanghai, China
e Pfizer Inc, Pearl River, NY, USAa r t i c l e i n f o
Article history:
Received 24 June 2015
Received in revised form 18 August 2016
Accepted 24 August 2016
Available online 8 September 2016
Keywords:
PCV7
S. pneumoniae
Antibody persistence
Chinaa b s t r a c t
Background: In a previous study, Chinese infants were vaccinated with 7-valent pneumococcal conjugate
vaccine (PCV7)P7 days before routine diphtheria, tetanus, and acellular pertussis vaccine (DTaP); PCV7
administered concomitantly with DTaP (PCV7 + DTaP); or DTaP alone. This study examined antibody per-
sistence at a single time point 3 years after the last vaccination.
Methods: Children who participated in the prior PCV7 study were eligible to participate. A single blood
sample was drawn at enrollment. Immunoglobulin G (IgG) geometric mean concentrations (GMCs) speci-
fic to the PCV7 serotypes and percentages of subjects with IgGP0.35 lg/mL were compared for subjects
receiving PCV7 versus PCV7 + DTaP (concomitant) and for PCV7 or PCV7 + DTaP (concomitant) versus
DTaP alone. IgG concentrations at 3 years after the last vaccination were also compared with those after
the infant series and toddler dose.
Results: Three years after the last vaccination with PCV7 or PCV7 + DTaP (concomitant), IgG GMCs for
most PCV7 serotypes were lower than after the infant series or toddler dose but remained above prevac-
cination concentrations. IgG GMC were similar between the PCV7 and PCV7 + DTaP (concomitant) groups
for 5 out of 7 serotypes but serotypes 4 and 19F were significantly lower in the PCV7 + DTaP (concomi-
tant) recipients. Three years after the last vaccination, IgG GMCs were significantly higher for 6 of 7 PCV7
serotypes among those receiving PCV7 or PCV7 + DTaP (concomitant) compared with recipients of DTaP
alone. Among subjects receiving DTaP alone, serotype-specific antibody concentrations were significantly
higher for all serotypes 3 years after the last vaccination compared with after the infant series.
Conclusion: Three years after PCV7 vaccination, serotype-specific antibodies were lower than after the
primary infant series but higher than prevaccination levels and higher among subjects who received
PCV7 compared with those who did not. The immune response was comparable in children who received
PCV7 with and without concomitant DTaP.
Clinical Trial Registration: NCT01298544
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Streptococcus pneumoniae is a leading cause of acute otitis
media, pneumonia, and invasive disease in children globally
[1,2]. In China, pneumococcal disease remains a significant cause
of morbidity and mortality in children <5 years of age [3]. A 7-
valent pneumococcal conjugate vaccine (PCV7) containing the cap-
sular polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F
5360 R. Li et al. / Vaccine 34 (2016) 5359–5365was approved for use in China in 2008 [4]. During the period of the
study, PCV7 was available in the private market in China but had
not been incorporated into the routine infant immunization
schedule.
Licensure of PCV7 for use in China was based on a clinical study
conducted by Li and colleagues in Chinese infants that assessed the
immunogenicity and safety of PCV7 in conjunction with the rou-
tine diphtheria, tetanus, and acellular pertussis vaccine (DTaP)
[5]. Infants were randomized to receive 1 of 3 dosing schedules
at 3, 4, and 5 months of age (infant series): PCV7 P7 days before
DTaP, PCV7 concomitant with DTaP, or DTaP alone. All infants vac-
cinated with PCV7 received a toddler dose between 12 and
15 months of age [5].
This postlicensure study assessed antibody persistence in chil-
dren who participated in the original clinical study of PCV7 con-
ducted by Li and colleagues. The objectives were to assess
persistence of serotype-specific antibodies at a single time point
3 years after the last vaccination among children who received
PCV7 with or without concomitant DTaP vaccination, and to assess
serotype-specific antibody levels after 3 years in children receiving
PCV7 versus DTaP alone.
2. Methods
2.1. Study design and subjects
This study enrolled children who had participated in the PCV7
study described above [5], were in general good health, and had
parental consent for participation. The study investigator was
responsible for contacting all former participants by telephone.
Data were collected at least 3 years after the last vaccination and
were derived from analysis of a single blood sample drawn at
enrollment. No vaccines were administered during this study.Table 1
Disposition of study subjects.
Vaccination
Subjects PCV7
Enrolled in prior registration study, n 300
Completed the prior registration study, n (%) 236 (78.7)
Screened for antibody persistence study 123
Assessed P3 y after the last vaccination, n (%) 123 (52.1)
Age at blood draw, years
Mean (SD) 5.04 (0.144
Minimum, maximum 4.7, 5.4
DTaP = routine diphtheria, tetanus, and acellular pertussis; PCV7 = 7-valent pneumococc
Table 2
Pneumococcal IgG GMCs (lg/mL) 3 years after the last vaccination with PCV7 or PCV7 + D
Serotype PCV7 PCV7 + DTaP PCV7 + DTaP/PCV7
n = 120–123a n = 120–121a
GMCb (95% CIc) GMCb (95% CIc) Ratiod (95% CIe)
4 0.98 (0.77, 1.23) 0.66 (0.52, 0.84) 0.68 (0.48, 0.94)
6B 11.35 (9.71, 13.27) 9.24 (7.66, 11.16) 0.81 (0.64, 1.04)
9V 1.35 (1.13, 1.62) 1.29 (1.08, 1.54) 0.95 (0.74, 1.23)
14 4.5 (3.38, 5.98) 3.02 (2.25, 4.05) 0.67 (0.45, 1.01)
18C 0.8 (0.66, 0.97) 0.77 (0.6, 0.98) 0.96 (0.7, 1.31)
19F 10.14 (8.06, 12.75) 5.67 (4.5, 7.14) 0.56 (0.4, 0.77)
23F 3.31 (2.8, 3.91) 2.71 (2.26, 3.25) 0.82 (0.64, 1.05)
CI = confidence interval; DTaP = routine diphtheria, tetanus, and acellular pertussis;
pneumococcal conjugate vaccine.
a Number of subjects with a determinate IgG antibody concentration to the given ser
b GMCs were calculated using all subjects with available data for the specified blood
c CIs are back transformations of confidence levels based on the Student t distributio
d Ratios of GMCs are calculated by back transforming the ratio difference between va
e CIs for the ratio are back transformations of a CI based on the Student t distributionSubjects were evaluated according to the vaccine group to which
they were assigned in the original trial: PCV7 administeredP7 days
before DTaP (PCV7), PCV7 + DTaP administered concomitantly
(PCV7 + DTaP), or DTaP alone.
Subjects were excluded for vaccination with any pneumococcal
vaccine in the period between completion of the initial study and
enrollment in the post-licensure study, or if they had a history of
pneumococcal disease; immunodeficiency; receipt of blood prod-
ucts, including immunoglobulin, within 12 weeks of the study
start; or any acute or chronic medical condition deemed by the
study investigator to be injurious to the subject or a source of
potential bias for the study. Subjects who did not receive PCV7 dur-
ing the initial trial were offered PCV7 after their participation in
this study. This study was conducted in accordance with the Inter-
national Conference on Harmonisation (ICH) Guideline for Good
Clinical Practice (GCP) and the ethical principles that have their
origins in the Declaration of Helsinki.
2.2. Immunogenicity evaluations
The primary immunogenicity objective was to evaluate
immunoglobulin G (IgG) concentrations specific to the 7 pneu-
mococcal vaccine serotypes 3 years after administration of the
toddler dose of PCV7 with or without concomitant DTaP. The sec-
ondary immunogenicity objective was to compare IgG concentra-
tions specific to the PCV7 serotypes in children who received
PCV7 or PCV7 + DTaP versus DTaP only. For antibody assessment,
a 5-mL blood sample was collected at enrollment. The standard-
ized WHO ELISA was performed as describe using the interna-
tional reference standard serum, 89SF, to calculate all ELISA
results, [6,7]. The assays were carried out in double-absorbent
assay conditions with pneumococcal cell wall polysaccharide
(CWPS) and serotype 22F pneumococcal polysaccharide (CWPS2),schedule
PCV7 + DTaP DTaP
296 204
238 (80.4) 178 (87.3)
121 91
121 (50.8) 91 (51.1)
) 5.04 (0.157) 5.04 (0.151)
4.7, 5.4 4.7, 5.4
al conjugate vaccine; SD = standard deviation.
TaP (concomitant).
PCV7 or PCV7 + DTaP DTaP PCV7 or PCV7 + DTaP/DTaP
n = 241–244a n = 84–91a
GMCb (95% CIc) GMCb (95% CIc) Ratiod (95% CIe)
0.8 (0.68, 0.95) 0.41 (0.29, 0.58) 1.97 (1.39, 2.8)
10.26 (9.08, 11.59) 3.37 (2.76, 4.13) 3.04 (2.41, 3.84)
1.32 (1.16, 1.5) 1.05 (0.83, 1.32) 1.26 (0.98, 1.62)
3.69 (3.01, 4.53) 0.55 (0.4, 0.76) 6.66 (4.53, 9.79)
0.78 (0.67, 0.92) 0.34 (0.24, 0.47) 2.34 (1.68, 3.24)
7.6 (6.44, 8.97) 1.7 (1.35, 2.15) 4.47 (3.29, 6.07)
2.99 (2.65, 3.39) 1.44 (1.17, 1.76) 2.08 (1.65, 2.63)
GMC = geometric mean concentration; IgG = immunoglobulin G; PCV7 = 7-valent
otype.
draw.
n for the mean logarithm of the concentrations.
ccine groups on the logarithmic scale.
for the difference of the logarithms of the measures.
Fig. 1. IgG GMC response curves for the 7 pneumococcal serotypes in subjects vaccinated with PCV7, PCV7 + DTaP (concomitant), or DTaP. DTaP = routine diphtheria, tetanus,
and acellular pertussis; GMC = geometric mean concentration; IgG = immunoglobulin G; PCV7 = 7-valent pneumococcal conjugate vaccine.
R. Li et al. / Vaccine 34 (2016) 5359–5365 5361as recommended by the WHO guidelines [8]. Briefly, coated ELISA
plates were washed with Tris-buffered saline containing 0.1%
Brij-35 detergent. Diluted serum samples were applied to the
assay plates in double absorbent buffer, and the reference stan-
dard serum, 89SF, was prepared in single absorbent buffer condi-
tions, per WHO guidelines [8]. Serotype-specific IgG antibodies
were detected with an alkaline phosphatase (AP) conjugatedanti-human IgG secondary antibody. The chromogenic AP sub-
strate, p-nitrophenylphosphate was dissolved in 1 M diethanola-
mine with 0.5 mM magnesium chloride and added to reaction
wells. Optical densities were measured on a spectrophotometer
at 405 nm with a reference wavelength of 690 nm. Serum IgG
antibody concentration were calculated from the 89SF reference
standard curve using log-log linear regression.
5362 R. Li et al. / Vaccine 34 (2016) 5359–53652.3. Statistical analysis
2.3.1. Immunogenicity
Immunogenicity comparisons of IgG concentrations between
groups included subjects receiving PCV7 versus PCV7 + DTaP (con-
comitant) and between PCV7 or PCV7 + DTaP (concomitant) versus
DTaP alone at 3 years after the last vaccination. Within each group,
formal statistical IgG GMC comparisons were performed after the
infant series to 3 years after the last vaccination and after the tod-
dler dose to 3 years after the last vaccination. In accordance with
the National Immunization Schedule in China, subjects receiving
DTaP only received the 3-dose infant series but did not receive a
toddler vaccination, therefore, serology before and after the toddler
dose was not collected for this group. Assessments were made for
the all-available population (subjects with P1 valid assay result).
Pneumococcal IgG geometric mean concentrations (GMCs)
were calculated for each visit with a blood sampling; geometric
mean fold changes (GMFCs) were summarized by GMCs and confi-
dence intervals (CIs), computed using the logarithmically trans-
formed assay results. For between-group comparisons, ratios of
the GMCs for the groups being compared were calculated by back
transforming the difference between vaccine groups on the loga-
rithmic scale. For within-group comparisons, the GMFCs for the
time points were calculated by back transforming the difference
in GMC within vaccine groups on the logarithmic scale. The
response was considered significantly greater if the lower limit of
the 95% CI for the ratio of GMCs was >1.0 and was considered sig-
nificantly lower if the upper limit of the 95% CI for the ratio of GMC
was <1.0. The proportion of subjects achieving an antibody concen-
tration P0.35 lg/mL was computed for each serotype, and exact,
unconditional, 2-sided 95% CIs on the proportion were calculated.
The response (in proportion for 2 groups) was considered signifi-
cantly greater if the lower limit of the 95% CI for the difference
in proportion was >0.0 and was considered significantly lower if
the upper limit of the 95% CI for the difference in proportion was
<0.0. Antibody response curves and reverse cumulative distribu-
tion curves were presented graphically by group for each
serotype-specific pneumococcal IgG concentration prevaccination
and postvaccination.3. Results
3.1. Study population
Of 652 subjects who completed the initial study, 336 subjects
were screened, and 335 were enrolled and assessed according to
previous vaccination history: PCV7 (n = 123), PCV7 + DTaP (con-
comitant; n = 121), and DTaP (n = 91). The percentage of subjectsTable 3
Proportion of subjects with a pneumococcal IgG antibody concentration P0.35 lg/mL 3 y
Serotype PCV7 PCV7 + DTaP Differencec
n = 120–123a n = 120–121a (PCV7 + DTaP)–PCV7
% (95% CIb) % (95% CIb) (95% CId)
4 82.9 (75.1, 89.1) 64.5 (55.2, 73.0) 18.5 (29.4, 7.3)
6B 100 (97.0, 100) 100 (97.0, 100) 0 (3.1, 3.0)
9V 93.5 (87.6, 97.2) 94.2 (88.4, 97.6) 0.7 (5.9, 7.3)
14 95.1 (89.7, 98.2) 91.7 (85.3, 96.0) 3.4 (10.3, 3.1)
18C 81.3 (73.3, 87.8) 69.4 (60.4, 77.5) 11.9 (22.7, 1.0)
19F 100 (97.0, 100) 97.5 (92.9, 99.5) 2.5 (7.1, 0.6)
23F 100 (97.0, 100) 99.2 (95.5, 100) 0.8 (4.5, 2.3)
CI = confidence interval; DTaP = routine diphtheria, tetanus, and acellular pertussis; IgG
a Number of subjects with a determinate IgG antibody concentration to the given ser
b Exact 2-sided CI based on the observed proportion of subjects.
c Difference in proportions expressed as a percentage.
d Exact 2-sided CI for the difference.participating was similar in each of the three groups. Subjects in
the 3 vaccine groups were similar with respect to sex, race and
age; all subjects were Asian and older than 4 years (mean age,
5.04 years). Subject disposition is summarized in Table 1. All sub-
jects completed the study.3.2. Immunogenicity
At 3 years after the last PCV7 vaccination, GMCs for the majority
of the 7 serotypes were similar between recipients of PCV7 and
recipients of PCV7 + DTaP (concomitant) (Table 2); however, IgG
GMCs for serotypes 4 and 19F were significantly lower after
PCV7 + DTaP (concomitant) compared with PCV7. Among recipi-
ents of PCV7, with or without concomitant DTaP, compared with
DTaP alone, IgG GMCs were significantly higher for 6 of 7 sero-
types, although IgG GMC for serotype 9V was not significantly
higher among PCV7 recipients, the lower limit of the 95% CI was
0.98, which is very close to the limit for significance (lower limit
of the 95% CI for the ratio of GMCs >1.0; Table 2).
Compared with before vaccination, IgG GMCs at 3 years after
the last vaccination were higher for all serotypes in recipients of
PCV7 or PCV7 + DTaP (concomitant). In contrast, compared with
after the infant series, IgG GMCs at 3 years after the last vaccina-
tion were significantly lower for 5 of 7 serotypes (4, 9V, 14, 18C,
23F) in PCV7 recipients and 4 of 7 serotypes (4, 9V, 14, 18C) in
PCV7 + DTaP (concomitant) recipients; IgG GMCs were signifi-
cantly higher for serotype 6B in both groups. Among subjects vac-
cinated with DTaP alone, IgG GMCs were significantly higher for all
serotypes 3 years after the last vaccination compared with after
the infant series (Fig. 1, Supplementary Table 1). Compared with
after the toddler dose, IgG GMCs at 3 years after the last vaccina-
tion were lower for all serotypes in recipients of PCV7 or PCV7
+ DTaP (concomitant), being significantly lower for all 7 serotypes
in PCV7 recipients and significantly lower for 6 out of 7 serotypes
(except serotype 6B) in PCV7 + DTaP (concomitant) recipients
(Fig. 1, Supplementary Table 2).
At 3 years after the last vaccination, IgG concentrations were
P0.35 lg/mL for each of the 7 serotypes in >60% of subjects who
received PCV7 or PCV7 + DTaP (concomitant). The proportion of
responders ranged from 81.3% (serotype 18C) to 100% (serotypes
6B, 19F and 23F) among PCV7 recipients, and 64.5% (serotype 4)
to 100% (serotype 6B) among PCV7 + DTaP (concomitant) recipi-
ents (Table 3, Fig. 2). For the majority of serotypes, the proportion
of subjects with an IgG concentration P0.35 lg/mL was similar
between PCV7 recipients and PCV7 + DTaP (concomitant) recipi-
ents; the exceptions were serotypes 4 and 18C, for which the pro-
portions were significantly smaller among PCV7 + DTaP
(concomitant) recipients. Compared with subjects receiving DTaPears after the last vaccination.
PCV7 or PCV7 + DTaP DTaP Differencec
n = 241–244a n = 84–91a (PCV7 or PCV7 + DTaP)–DTaP
% (95% CIb) % (95% CIb) (95% CId)
73.8 (67.8, 79.2) 48.8 (37.7, 60.0) 25.0 (12.7, 37.0)
100 (98.5, 100) 97.8 (92.3, 99.7) 2.2 (0, 7.7)
93.8 (90.0, 96.5) 83.5 (74.3, 90.5) 10.3 (1.9, 19.6)
93.4 (89.6, 96.2) 63.7 (53.0, 73.6) 29.7 (19.4, 40.5)
75.4 (69.5, 80.7) 45.5 (34.8, 65.4) 30.0 (17.9, 41.5)
98.8 (96.4, 99.7) 92.2 (84.6, 96.8) 6.5 (1.2, 13.9)
99.6 (97.7, 100) 93.4 (86.2, 97.5) 6.2 (1.8, 13.0)
= immunoglobulin G; PCV7 = 7-valent pneumococcal conjugate vaccine.
otype.
Fig. 2. Reverse cumulative distribution curves for the 7 pneumococcal serotypes in subjects vaccinated with PCV7, PCV7 + DTaP (concomitant), or DTaP. DTaP = routine
diphtheria, tetanus, and acellular pertussis; PCV7 = 7-valent pneumococcal conjugate vaccine.
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or PCV7 + DTaP (concomitant) had IgG concentrations P0.35 lg/
mL, except for serotype 6B (Table 3). Among subjects receiving
DTaP alone, >60% had IgG concentrations P0.35 lg/mL for 5 of 7
serotypes; exceptions were serotype 4 (48.8%) and 18C (45.5%;
Table 3, Fig. 2).4. Discussion
In the 3-year interval between the toddler dose of PCV7 and this
analysis, circulating serotype-specific IgG antibody geometric
means had declined for all 7 serotypes in the vaccine, but remained
higher than antibody levels before the infant series and before the
toddler dose. Children who had not been previously vaccinated
with PCV7 developed serotype-specific antibodies during the inter-
val between their last DTaP vaccination and this analysis. We sur-
mise that this increase in serotype-specific PCV7 antibodies is a
result of exposure to naturally circulating S. pneumoniae; however,
a lack of epidemiological studies in the Guangxi region preclude
establishing causality. A study conducted by Xue et al. in 2010
reported pneumococcal serotype distribution in 11 provinces,
which included Guangxi [9]; however, data were not broken out
by province and are based on hospital isolates. Therefore, it is dif-
ficult to infer which serotypes may be routinely circulating in this
region. Broader epidemiologic studies have shown that all of the
PVC7 serotypes are circulating in China, either as disease-causing
or nasopharyngeal isolates [10–24]. Overall, serotype-specific anti-
body concentrations remained higher in PCV7-vaccinated children
compared with those vaccinated with DTaP alone and were statis-
tically significantly higher for all serotypes except 9V. A small
number of regional studies have shown that serotype 9V circulates
at a relatively low level in China [14,16,17,19,20,24] and decreased
in the elderly after the introduction of PCV7 [21]. Results of our
study are consistent with data from the Finnish Otitis Media (Fin-
nOM) study where antibody concentrations 4 years after immu-
nization were found to be higher than placebo recipients [25].
Antibody persistence for most serotypes was generally comparable
regardless of whether PCV7 was administered before or concomi-
tantly with DTaP. The exceptions were serotypes 4 and 19F, both
of which had a reduced antibody response when PCV7 was admin-
istered with DTaP. While the cause of this decrease is not clear, a
study conducted by Schmitt et al. determined that there was no
interaction between PCV7 and a concomitantly-administered
DTaP-IPV-Hib vaccine [26].
In PCV7 recipients, the percentage of subjects with an IgG anti-
body concentration P0.35 lg/mL was P93.4 for all serotypes,
except serotypes 4 and 18C (73.8% and 75.4%, respectively). This
is consistent with antibody persistence reported 4 years after
PCV7 in the FinnOM study, wherein the percentage of subjects
with IgG antibody concentrations P0.35 lg/mL were higher for
commonly circulating serotypes such as 6B and 19F (96% and
98%, respectively) compared with serotypes that were less com-
mon, such as serotypes 4 and 18C (64% and 73%) [25]. Our results
are also consistent with a study conducted in the UK in which
infants received PCV7 at 2, 4, and 12 months; when assessed at
3.5 years of age, the percentage of children with IgG antibody con-
centrations P0.35 lg/mL were higher for serotypes 6B and 19F
(98% and 94%, respectively) and lower for serotypes 4 and 18C
(42% and 38%) [27]. With the exception of serotypes 4 and 19F,
the percentage of children reaching an IgG antibody concentration
of 0.35 lg/mL 3 years after their last PCV7 vaccination was similar
regardless of whether PCV7 was administered with or without
DTaP.
There are certain limitations that should be considered when
evaluating the results of this study. Because antibodies wereassessed at a single time point, it was not possible to evaluate
the rate of antibody reduction before this 3-year postvaccination
assessment. In addition, the presence of long-lived memory B cells,
which arise through immunization with protein conjugate vacci-
nes, was not assessed nor were functional antibody or cellular
responses. Baseline antibody results, taken together with serum
antibody responses after the infant series and toddler dose and
3 years after the last dose, provide a comprehensive picture of
the immune response to each serotype over time. Another limita-
tion of this study is the substantial number of subjects who were
lost to follow-up after the initial study. Screening for this study
was performed by the study investigator who contacted former
participants by telephone using contact information that had been
submitted three years prior. The combination of outdated contact
information and changes in domicile, which is not uncommon
among women who give birth in Southern China, is the primary
reason that subjects were lost to follow-up. Although the number
of subjects lost to follow-up was high, equal proportions of sub-
jects from each vaccine group participated in the current study.
In conclusion, serotype-specific circulating IgG antibodies to
PCV7 decreased over time. Three years after PCV7 vaccination,
serotype-specific antibody concentrations were lower compared
with after the primary immunization series and booster dose, but
higher than prevaccination concentrations and higher compared
with those in children who had not received PCV7 vaccination.
The immune response was comparable in children who received
PCV7 with and without concomitant DTaP.
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